SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-072552
Filing Date
2023-03-16
Accepted
2023-03-16 16:01:17
Documents
14
Period of Report
2023-03-16
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d488076d8k.htm   iXBRL 8-K 24576
2 EX-99.1 d488076dex991.htm EX-99.1 54068
6 GRAPHIC g488076g34r01.jpg GRAPHIC 7655
  Complete submission text file 0001193125-23-072552.txt   221002

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA cbay-20230316.xsd EX-101.SCH 2850
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE cbay-20230316_lab.xml EX-101.LAB 17994
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE cbay-20230316_pre.xml EX-101.PRE 11261
8 EXTRACTED XBRL INSTANCE DOCUMENT d488076d8k_htm.xml XML 3353
Mailing Address 7575 GATEWAY BOULEVARD SUITE 110 NEWARK CA 94560
Business Address 7575 GATEWAY BOULEVARD SUITE 110 NEWARK CA 94560 510-293-8800
CymaBay Therapeutics, Inc. (Filer) CIK: 0001042074 (see all company filings)

IRS No.: 943103561 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36500 | Film No.: 23738690
SIC: 2834 Pharmaceutical Preparations